Anticoagulants for atrial fibrillation: why is the treatment rate so low? - Wikidata - awgldk - TriplyDB

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

http://www.wikidata.org/entity/Q34958223

about

Self-monitoring and self-management of oral anticoagulation Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient records Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran Self-monitoring and self-management of oral anticoagulation Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation Optimising stroke prevention in non-valvular atrial fibrillation Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.Impact of stated barriers on proposed warfarin prescription for atrial fibrillation: a survey of Canadian physicians.Oral heparin: status review Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.Do physician outcome judgments and judgment biases contribute to inappropriate use of treatments? Study protocol.Treatment patterns associated with stroke prevention in patients with atrial fibrillation in three major cities in the People's Republic of china.A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals.New frontiers for stroke prevention in atrial fibrillation.Preparation and optimization of N-trimethyl-O-carboxymethyl chitosan nanoparticles for delivery of low-molecular-weight heparin.The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.Decision-making interventions to stop the global atrial fibrillation-related stroke tsunami.Stroke Prevention in Atrial Fibrillation in the Very Elderly: Anticoagulant Therapy Is No Longer a Sin.The prestroke use of vitamin K antagonists for atrial fibrillation - trends over 15 years.Implementation of an emergency department atrial fibrillation and flutter pathway improves rates of appropriate anticoagulation, reduces length of stay and thirty-day revisit rates for congestive heart failure.Patient-centered medical homes and oral anticoagulation therapy initiation.[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].

P2860

Q24235798-6DD3311E-B865-4731-831A-C0FABDE6BF96 Q24800847-0E1CF3E7-BAE0-46E0-BC1E-F8DFB9060AE8 Q24807132-266AFE54-5297-47C0-918D-1705A5EBBABF Q26471166-97CE6CC3-D188-4896-B6F1-7AF3EE958372 Q28176666-E1916697-3A49-4D25-B69D-56AAE4F80430 Q28200609-7DC7B955-D2E9-4938-B1F2-F8C19C1AD2C2 Q28212575-F0779A94-6B3E-44AD-A4E6-1B4BCEAD75F4 Q33823354-AB7C4636-9220-4303-9D63-D52CF610A303 Q34087971-4B41F056-5FA8-4279-A64B-47E523E8F426 Q34893606-5928312C-EC2F-42FE-BE51-C2D7BF73947C Q35583944-C0E1ABC8-1D47-445F-95F4-88D8622B5F19 Q35855776-E366F75B-0DA2-4980-B06B-3521F455A617 Q37412464-1010143F-32AF-4182-9B2B-1F16A32B8EA0 Q37590855-4E08E909-9F25-45C9-919C-7E421D016F54 Q37977275-EC0AB419-A01D-437A-9091-FC3ADE4E63EB Q38953388-E8E1F884-9F0F-407B-96D0-DA05215A06EA Q38984688-CA7EC74B-719B-4CAB-B648-EF2F89E37FDC Q40256282-5B59BF25-353C-456A-81E7-23F94148544E Q42354433-09772BDE-984B-4FD9-86E9-8159F4FD7401 Q43533823-DBD44A0C-825B-4B35-A1C7-1766C1BFC4EA Q50104161-FCE0C111-FE3D-4086-9B13-50E2D26E4C55 Q51139933-D2141675-92EA-42DA-8B9C-E690BE141376 Q52887413-3EDF379F-86A3-4CD8-A34F-8414580C7FE7

P2860

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

http://www.wikidata.org/entity/Q34958223

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@ast

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@en

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@nl

type

label

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@ast

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@en

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@nl

prefLabel

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@ast

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@en

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@nl

P1433

Q34958223-C48111FC-3FD0-45B6-871D-2F38D01B9C22

P1476

Q34958223-9E884E4D-FF57-476D-8BB7-59D34A69008F

P2093

Q34958223-E49C7369-0A95-49F3-9BBC-E9341D761963

Q34958223-EA0A8AA4-32A0-4FEE-A21F-73FE2C9628F4

P2860

Q34958223-13ADBC85-7A2D-45BF-9A5A-B25E8C79DB22

Q34958223-421946F7-A227-477F-951F-F8E4F521E39A

Q34958223-58A712AE-E50C-4E9A-873F-D238C75F1E24

Q34958223-5B1BD528-D398-44DD-8460-9FC832D8882E

Q34958223-85E4934D-D2DC-49B2-8156-D50D718E2320

Q34958223-B2C110DF-A891-4BD5-8313-58F442FA3553

Q34958223-BDD507B8-35EB-42C2-A8ED-E5196CD4ACEC

Q34958223-EC5C838B-382F-42B3-AFF4-7306130F4CA1

P304

Q34958223-BE129EF0-2E38-4674-B2B5-A0C4642A1F9C

P31

Q34958223-275DF293-C7E2-4749-A752-D9BC13B1C957

P356

Q34958223-D3B77FAF-F0F5-4EA3-8820-73F5817B79C0

P433

Q34958223-995FB795-CB7E-453B-8245-62829F7555C3

P478

Q34958223-EC884C12-A04C-4C3B-88CB-D48D3DC714B9

P577

Q34958223-519923C4-6DF3-40E0-A4BF-187FFA3EB84E

P5875

Q34958223-DFBCA7EC-95CE-4D80-9A4D-970346E39599

P698

Q34958223-5D9F585D-32D1-4B00-9E6D-0368BFEF6D8A

P921

Q34958223-532549BA-4C2E-4149-BB5B-0629499862D1

Q34958223-E1776CB3-6EEF-4D68-B269-90DCB71E6A65

P932

Q34958223-50A1FF8E-73C2-4206-845E-AAB03430E903

P356

P1433

Clinical Cardiology

P1476

Anticoagulants for atrial fibrillation: why is the treatment rate so low?

@en

P2093

Robert Hatala

http://www.w3.org/2001/XMLSchema#string

Thomas A Buckingham

http://www.w3.org/2001/XMLSchema#string

P2860

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.

Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.

Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners.

Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association.

Warfarin use among patients with atrial fibrillation.

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals.

P304

447-454

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CLC.4960251003

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227910565

http://www.w3.org/2001/XMLSchema#string

P698

12375802

http://www.w3.org/2001/XMLSchema#string

P921

anticoagulation

atrial fibrillation

P932

6654570

http://www.w3.org/2001/XMLSchema#string